NextMeds vs Collective
At one seller the membership is the price; at the other it is billed beside it.
NextMeds
Editorial
$129/mo
NextMeds sells its GLP-1 treatment as a membership, and the membership price is the whole price: $129 a month for compounded semaglutide and $179 for compounded tirzepatide. Telehealth visits, a care coach, a dietitian and shipping sit inside it. Both rates are described as the same at every dose, and a promotion advertising $100 a month runs under a countdown timer beside it.
Pick it for: Readers who want one charge covering the whole service
Collective
Editorial
$76/mo
Collective advertises $59 a month for compounded semaglutide and $69 for compounded tirzepatide, and charges a $199 annual membership beside both. Added together, a first year of semaglutide comes to $907, or $76 a month. The rate is stated as holding at every dose.
Pick it for: Readers who want the medication priced apart from the service
Our verdict
NextMeds states the published figure IS the membership, bundling visits, coaching and shipping. Collective bills its membership separately from the medication. The word is the same and the arrangement is not.
What actually separates them
NextMeds and Collective state different things about published price. Everything else they publish, they publish the same way.
NextMeds costs $53 more than Collective — 70% more for the same molecule. Whether that buys anything is what the rest of this page is for.
Over twelve months that is about $912 at Collective against $1,548 at NextMeds — a difference of $636.
| NextMeds | Collective | |
|---|---|---|
| Published price | $129/mo | $76/mo |
Before you choose either
Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against every published price we hold rather than against each other alone.
Our take is computed from a published rubric that does not read commercial status, and what is known about safety applies to both of them equally.